1887
Volume 2022, Issue 2
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

While there is no universal agreement on the benefits of convalescent plasma (CP) in the treatment of COVID-19 infection, very little is known about whether CP affects the association between chronic diseases and mortality. It is known that chronic diseases are associated with worse outcomes, but it is not clear whether the transfusion of CP impacts this association. This study aims to evaluate this impact considering that few studies have discussed the treatment of COVID-19 patients with CP. A cross-sectional study was conducted among COVID-19 patients treated with CP at the main hospital for treatment and isolation of COVID-19 in Anbar/Iraq during the period of May to August 2020. A questionnaire on socio-demographic characteristics, smoking, and contact with COVID-19 was conducted. The presence of comorbidity, especially hypertension, heart failure, coronary artery disease, diabetes mellitus, chronic pulmonary diseases, asthma, and the hospital outcome (discharged home alive or cure/death) were included. The Chi-square test (or Fisher's exact test) was used to measure the association between comorbidity with the outcome. Logistic regression was used to assess the main predictors for cure (discharged home alive) and death outcome. The mean age of the subjects was (53.05 ± 15.16), with a higher death rate among the older age group, especially those over 60-year with non-survivors at age of 65 or more. There was a statistically significant association between the presence of comorbidity and the mortality rate (P < 0.001). Subjects with chronic disease had a 5 times higher risk for death due to COVID-19 in comparison to those without the chronic disease (OR = 5.8, C.I. = 2.01-16.96, P = 0.001), hypertension showed the highest predictor (C.I = 1.43- 22.29, p = 0.013). Smoking and gender were not associated with mortality. The present study found a high mortality rate among COVID-19 patients treated with CP, specially for those with age over 60, or with comorbidities.

Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2022.13
2022-02-04
2022-09-28
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2022/2/jemtac.2022.13.html?itemId=/content/journals/10.5339/jemtac.2022.13&mimeType=html&fmt=ahah

References

  1. Chen N, Zhou M, Dong X, Qu J, Gong F, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15; 395:(10223):507–513.
    [Google Scholar]
  2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22; 395:(10224):565–574.
    [Google Scholar]
  3. World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. [internet] [Accessed September 30, 2020]. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-1911-march-2020.
    [Google Scholar]
  4. Brainard J. Scientists are drowning in COVID-19 papers. Can new tools keep them afloat. Science. 2020 May 13;:13.
    [Google Scholar]
  5. Al-Ani A. Reactive lymphocytes in blood film of a covid-19 iraqi patient: a case report. Hematol Transfus Cell Ther. 2020 Oct;42:57–8.
    [Google Scholar]
  6. Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clinical Medicine. 2020 Mar; 20:(2):124.
    [Google Scholar]
  7. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. BMJ. 2020 May 12;:369:m1808. doi: 10.1136/bmj.m1808.
    [Google Scholar]
  8. Chen L., Xiong J., Bao L., Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis. 2020; 20:(4):398–400.
    [Google Scholar]
  9. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006 Oct 17; 145:(8):599–609.
    [Google Scholar]
  10. Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc. 2020 Sep;95(9):1888–1897. doi: 10.1016/j.mayocp.2020.06.028.
    [Google Scholar]
  11. MacLennan S, Barbara JAJ. Risks and side effects of therapy with plasma and plasma fractions. Best Pract Res Clin Haematol. 2006; 19:(1):169–189.
    [Google Scholar]
  12. Sanfilippo F, La Rosa V, Astuto M. Micro-Thrombosis, Perfusion Defects, and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma. Mayo Clin Proc. 2021 Jan; 96:(1):259.
    [Google Scholar]
  13. Capuano A, Rossi F, Paolisso G. Covid-19 kills more men than women: An overview of possible reasons. Frontiers in Cardiovascular Medicine. 2020 Jul 17;:7:131.
    [Google Scholar]
  14. Gupta R, Agrawal R, Bukhari Z, Jabbar A, Wang D, Diks J, et al. Higher comorbidities and early death in hospitalized African-American patients with Covid-19. BMC Infectious Diseases. 2021 Jan; 21:(1):1–11.
    [Google Scholar]
  15. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. SN comprehensive clinical medicine. 2020 Jun 25:1–8.
    [Google Scholar]
  16. Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID- 19 severity: A systematic review and meta- analysis. Journal of Medical Virology. 2020 Aug; 93:(2):1045–56.
    [Google Scholar]
  17. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID- 19: evidence from meta-analysis. Aging (Albany NY). 2020 Apr 8; 12:(7):6049–57.
    [Google Scholar]
  18. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. Jama. 2020 May 26; 323:(20):2052–9.
    [Google Scholar]
  19. Abdullah HM, Hama-Ali HH, Ahmed SN, Ali KM, Karadakhy KA, Mahmood SO, et al. Severe refractory COVID-19 patients responding to convalescent plasma; A case series. Annals of medicine and surgery. 2020 Aug 1;:56:125–7.
    [Google Scholar]
  20. FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID–19 Treatment, Another Achievement in Administration's Fight Against Pandemic [Internet]. Maryland: FDA; 2020 [Accessed 23 August, 2020]. Available from: https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment .
    [Google Scholar]
  21. Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. New England Journal of Medicine. 2021 Feb 18; 384:(7):619–29.
    [Google Scholar]
  22. Sostin OV, Rajapakse P, Cruser B, Wakefield D, Cruser D, Petrini J. A matched cohort study of convalescent plasma therapy for COVID- 19. Journal of clinical apheresis. 2021; 36:(4):523–532.
    [Google Scholar]
  23. Pinchoff J, Austrian K, Rajshekhar N, Abuya T, Kangwana B, Ochako R, et al. Gendered economic, social and health effects of the COVID-19 pandemic and mitigation policies in Kenya: evidence from a prospective cohort survey in Nairobi informal settlements. BMJ Open. 2021; 11:(3):e042749.
    [Google Scholar]
  24. United State of America Centers for Disease Control and Prevention. Evidence is used to update the list of underlying medical conditions that increase a person's risk of severe illness from COVID-19 [Internet]. Atlanta: CDC; 2020 [accessed 2 November 2020]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html .
    [Google Scholar]
  25. United Kingdom National Health Service. People are at higher risk from coronavirus. [Internet]. UK: NHS; 2020 [accessed November 16, 2020]. Available from: https://www.nhs.uk/conditions/coronavirus-covid-19/people-at-higher-risk/whos-at-higher-risk-from-coronavirus/.
    [Google Scholar]
  26. European Centre for Disease Prevention and Control. COVID-19, Latest evidence, Risk factors, and risk groups. [Internet]. ECDC; 2020 [accessed November 16, 2020]. Available from: https://www.ecdc.europa.eu/en/covid-19/latest-evidence/epidemiology.
    [Google Scholar]
  27. Cen Y, Chen X, Shen Y, Zhang XH, Lei Y, Xu C, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019—a multi-center observational study. Clinical Microbiology and Infection. 2020 Sep 1; 26:(9):1242–7.
    [Google Scholar]
  28. Xia X, Li K, Wu L, Wang Z, Zhu M, et al. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood, The Journal of the American Society of Hematology. 2020 Aug 6; 136:(6):755–9.
    [Google Scholar]
  29. Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clinical microbiology and infection. 2004 Jul; 10:(7):676–8.
    [Google Scholar]
  30. Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, Esteban I, et al. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J Med. 2021 Feb 18; 384:(7):610–618.
    [Google Scholar]
  31. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open-label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020 Oct 22;:371.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/jemtac.2022.13
Loading
/content/journals/10.5339/jemtac.2022.13
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): comorbidityconvalescent plasma therapyCOVID-19 and Iraq

Most Cited This Month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error